Apr 30, 2026 08:00AM
Apr 15, 2026 08:00AM
Aug 5, 2025 08:01AM
Aug 5, 2025 08:00AM
May 27, 2025 08:00AM
May 15, 2025 08:00AM
May 5, 2025 08:00AM Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
Apr 29, 2025 08:00AM
Jul 11, 2024 06:40PM
Jun 2, 2024 08:56PM
Jun 2, 2024 08:38PM
Aug 1, 2023 08:00AM
Jul 31, 2023 08:00AM
Jul 31, 2023 08:00AM Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
Jul 28, 2023 08:00AM
Jun 27, 2023 08:00AM
Jun 5, 2023 08:00AM
May 26, 2023 08:00AM
May 25, 2023 08:00AM
May 24, 2023 08:00AM
May 16, 2023 08:00AM Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
May 2, 2023 08:00AM
May 1, 2023 08:00AM
Apr 27, 2023 08:00AM
Apr 17, 2023 09:00AM
Mar 31, 2023 08:01AM
Mar 31, 2023 08:00AM
Mar 30, 2023 08:00AM Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Mar 14, 2023 08:00AM
Jan 30, 2023 08:00AM
Jan 4, 2023 08:00AM
Dec 23, 2022 08:00AM
Dec 8, 2022 08:00AM
Nov 29, 2022 08:00AM
Nov 10, 2022 11:11AM Immutep (IMMP) Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC
Nov 10, 2022 11:10AM
Nov 10, 2022 09:00AM
Nov 9, 2022 08:00AM
Nov 4, 2022 08:00AM
Nov 2, 2022 08:00AM
Oct 26, 2022 08:00AM
Oct 25, 2022 08:00AM Immutep Quarterly Activities Report
Oct 4, 2022 08:00AM
Sep 14, 2022 08:00AM
Aug 1, 2022 08:00AM
Jul 28, 2022 08:00AM
Jul 6, 2022 08:00AM
May 18, 2022 08:00AM
Apr 29, 2022 08:00AM Immutep Quarterly Activities Report
Mar 10, 2022 08:00AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All